GSK is evaluating potential cost-saving measures and manufacturing adjustments in Europe as it aims to invest in the launch of new products while moving away from older legacy drugs. City
Pharmaceutical
165Articles
Speculation surrounding a potential merger between GlaxoSmithKline and AstraZeneca has gained traction as GSK’s leadership undergoes a transition. Analysts recently suggested that the appointment of Luke Miels as GSK’s new
Orca Bio has secured 250 million USD in funding across two financing rounds, significantly strengthening its balance sheet as the company prepares for the potential commercialisation of its blood cancer
GSK has announced headline data from two pivotal phase III trials for bepirovirsen, a chronic hepatitis B treatment that could transform care for a disease affecting approximately 250 million people
Novo Nordisk has introduced the first oral formulation of its blockbuster GLP-1 weight loss medication to the United States market, marking a significant shift in the pharmaceutical landscape for obesity
The Danish pharmaceutical giant Novo Nordisk initiated a revolution in weight management with its groundbreaking therapies Ozempic and Wegovy. However, the company now faces a period of substantial upheaval following
Poolbeg Pharma has concluded a transformative year marked by substantial progress across its clinical pipeline, according to chief executive Jeremy Skillington in a recent interview. The biopharmaceutical company has advanced
AstraZeneca has initiated High Court proceedings against International Fire Consultants, seeking £32 million in damages for alleged widespread fire safety defects that reportedly caused significant delays to its £1.1 billion
Novo Nordisk has secured a significant regulatory victory, following the United States Food and Drug Administration’s approval of its new weight loss pill containing semaglutide. The decision delivers the Danish
Scotland’s National Health Service saw a dramatic increase in the prescription of semaglutide, known commercially as Ozempic and Wegovy, as the annual number of prescriptions rose to 168,486 in 2024
The United Kingdom has signed a new trade agreement with South Korea, projected to contribute an additional £400 million annually to its economy. This deal replaces the 2019 post-Brexit arrangement
The UK faces a surge in counterfeit weight loss injections as criminal groups target a lucrative and vulnerable market. Recent warnings from the pharmaceutical sector highlight an exponential rise in
Dame Emma Walmsley, departing chief executive of GSK, has emphasised the critical need for further improvements within the United Kingdom’s life sciences commercial environment. Speaking following the recent UK United
The pharmaceutical sector has welcomed the announcement by the Department of Health that the NHS rebate rate for newer medicines will fall to 14.5 per cent next year, down from
Illicit Weight Loss Drug Supplier Alluvi Persists with Unlicensed Sales After High Profile MHRA Raid
A company linked to the globe’s largest known seizure of illicit weight-loss medications remains active in the UK market despite regulatory intervention. Alluvi, the firm in question, continues to distribute
The United Kingdom is poised to provide NHS patients with access to new medicines previously deemed unaffordable under a sweeping agreement with the United States. Under the deal, NHS expenditure
